MX2007006919A - Formas cristalinas de un inhibidor del factor xa. - Google Patents

Formas cristalinas de un inhibidor del factor xa.

Info

Publication number
MX2007006919A
MX2007006919A MX2007006919A MX2007006919A MX2007006919A MX 2007006919 A MX2007006919 A MX 2007006919A MX 2007006919 A MX2007006919 A MX 2007006919A MX 2007006919 A MX2007006919 A MX 2007006919A MX 2007006919 A MX2007006919 A MX 2007006919A
Authority
MX
Mexico
Prior art keywords
crystalline forms
inhibitor
factor
phenyl
pharmaceutical compositions
Prior art date
Application number
MX2007006919A
Other languages
English (en)
Inventor
Mary F Malley
Steven R Fabian
Michael J Orwat
Roxana F Schlam
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2007006919A publication Critical patent/MX2007006919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La actual invencion proporciona formas cristalinas de 3-(1-hidroxi-1-metil-etil)-1-(4-metoxi-fenil)-6-[4-(2-oxo-2H-piri din-1-il)-fenil]-1,4,5,6-tetrahidro-pirazolo[3,4-c]piridin-7-ona y solvatos del mismo; proceso para la produccion de tales formas cristalinas; composiciones farmaceuticas que comprenden tales formas cristalinas; y metodos de tratamiento de trastornos tromboembolicos con tales formas cristalinas o tales composiciones farmaceuticas.
MX2007006919A 2004-12-15 2005-12-14 Formas cristalinas de un inhibidor del factor xa. MX2007006919A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18
PCT/US2005/045158 WO2006065853A2 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
MX2007006919A true MX2007006919A (es) 2007-06-26

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006919A MX2007006919A (es) 2004-12-15 2005-12-14 Formas cristalinas de un inhibidor del factor xa.

Country Status (15)

Country Link
US (2) US7371864B2 (es)
EP (1) EP1828187A2 (es)
JP (1) JP2008524228A (es)
KR (1) KR20070087606A (es)
AR (1) AR053990A1 (es)
AU (1) AU2005317158A1 (es)
BR (1) BRPI0519331A2 (es)
CA (1) CA2589886A1 (es)
IL (1) IL183825A0 (es)
MX (1) MX2007006919A (es)
NO (1) NO20072666L (es)
PE (1) PE20060739A1 (es)
RU (1) RU2007126770A (es)
TW (1) TW200634011A (es)
WO (1) WO2006065853A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285979B2 (en) 2008-05-27 2020-02-19 Dako Denmark A/S Hybridization compositions and methods
WO2010097656A1 (en) * 2009-02-26 2010-09-02 Dako Denmark A/S Compositions and methods for performing a stringent wash step in hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
WO2013057310A2 (en) 2011-10-21 2013-04-25 Dako Denmark A/S Hybridization compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A1 (en) * 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
BRPI0519331A2 (pt) 2009-01-20
KR20070087606A (ko) 2007-08-28
CA2589886A1 (en) 2006-06-22
IL183825A0 (en) 2007-09-20
US7371864B2 (en) 2008-05-13
US20080188517A1 (en) 2008-08-07
AU2005317158A1 (en) 2006-06-22
WO2006065853A3 (en) 2006-08-24
AR053990A1 (es) 2007-05-30
RU2007126770A (ru) 2009-01-27
WO2006065853A2 (en) 2006-06-22
NO20072666L (no) 2007-09-07
PE20060739A1 (es) 2006-08-16
EP1828187A2 (en) 2007-09-05
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
JP2008524228A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
MY148809A (en) Crystals of 1,2-dihydropyridine compound and their production process
ZA200306419B (en) Phenyl derivatives.
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
WO2004060313A3 (en) Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
WO2005034866A3 (en) Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
GB0504828D0 (en) Therapeutic agents
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
MX2007003471A (es) Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona.
AU2003228674A1 (en) Muscarinic antagonists
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EP2982668A3 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2007109799A3 (en) Polymorphs of eszopiclone malate
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
WO2005079464A3 (en) Vitamin d receptor antagonists and their use in treating asthma
MX2007006919A (es) Formas cristalinas de un inhibidor del factor xa.
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
MY157375A (en) Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone
WO2005019200A3 (en) Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration